Stock News and Filings Feed


Add MSC.H
to your dashboard

InMed Pharmaceuticals Added to CSE25 Index

2017-09-21 prnewswire
VANCOUVER, Sept. 21, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index. (6-0)

InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media

2017-09-20 marketwired
SEATTLE, WA--(Marketwired - Sep 20, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts. (9-0)

InMed Retains Consultant Ben Paterson for Biosynthesis Development

2017-09-19 prnewswire
VANCOUVER, Sept. 19, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for InMed's cannabinoid biosynthesis program. (6-0)

NetworkNewsWire Announces Publication Highlighting the Potential of Cannabinoid Biosynthesis

2017-09-14 marketwired
NEW YORK, NY--(Marketwired - Sep 14, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.

NetworkNewsWire Announces Publication Discussing Innovative Drug Developments in the Global Marijuana Market

2017-09-13 marketwired
NEW YORK, NY--(Marketwired - Sep 13, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.

Revive Therapeutics Appoints Dr. Ram Subramanian, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

2017-08-15 marketwired
TORONTO, ONTARIO--(Marketwired - Aug. 15, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that Dr. Ram Subramanian, M.D., will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases.

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

2017-07-13 marketwired
SEATTLE, WA--(Marketwired - Jul 13, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article covering InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) new research and development deal with ATERA SAS of France and the company's development of INM-750 for the treatment of epidermolysis bullosa (EB).

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media

2017-06-14 marketwired
SEATTLE, WA--(Marketwired - Jun 14, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc. (CNSX: IN) (OTCQB: IMLFF) and the progress it is making in advancing its lead clinical trial candidate.

Revive Therapeutics Announces Positive Results from its Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

2017-06-07 marketwired
TORONTO, ONTARIO--(Marketwired - June 7, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, announced today that it has obtained positive results from its research program of cannabinoid-based therapies targeting liver diseases, demonstrating certain cannabinoids being effective in a liver fibrosis model and may serve as novel treatments for liver fibrogenesis.

Revive Therapeutics Announces Sponsored Research Agreement with the University of Wisconsin-Madison to Evaluate a Novel Drug Delivery Technology Focused on Cannabinoids

2017-05-30 marketwired
TORONTO, ONTARIO--(Marketwired - May 30, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, announced today that it has entered into a sponsored research agreement with the University of Wisconsin-Madison to evaluate a novel drug delivery technology with a focus on cannabinoids for the potential to treat various diseases.

Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2017

2017-05-25 marketwired
TORONTO, ONTARIO--(Marketwired - May 25, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF) announced today its results for the three and nine months ended March 31, 2017. The unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the period may be viewed on SEDAR at www.sedar.com.

Seeking Alpha's Most Followed Marijuana Stocks: 1 Winner And 12 Losers, Post-Election

2016-12-18 seekingalpha
A value-weighted portfolio of the N=13 Seeking Alpha most followed marijuana stocks, purchased on Election Day, has already lost 30% of its value.